In clinic of thoracic surgery were operated on 2108 patients for various forms of pulmonary cancer, 218 (10.3%) of them--using videothoracoscopy (VTHS). In 141 (64.7%) patients the method of VTHS was applied for diagnostical purposes and in 55 (25.2%)--for treatment. Histological investigations of excised specimen showed planocellular cancer in 38 patients, adenocarcinoma--in 9, nonsmall cell carcinoma--in 6, anaplastic cancer--in 2. The operation cost while applying VTHS had constituted at average 648.65 US dollars, of thoracotomy--1283.5 US dollars.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Purpose: Clinical variables alone have limited ability to determine which patients will have recurrence after radical prostatectomy (RP). We evaluated the ability of locked multimodal artificial intelligence (MMAI) algorithms trained on prostate biopsy specimens to predict prostate cancer specific mortality (PCSM) and overall survival (OS) among patients undergoing radical prostatectomy with digitized RP specimens.
Materials And Methods: The Prostate, Lung, Colorectal, and Ovarian Cancer Screening Randomized Controlled Trial randomized subjects from 1993-2001 to cancer screening or control.
Insights into balloon pulmonary angioplasty and the WHO functional class of chronic thromboembolic pulmonary hypertension patients: findings from the CTEPH AC registry.
Cardiovasc Interv Ther
January 2025
Department of Cardiovascular Medicine, Kyushu University Graduate School of Medical Sciences, Fukuoka, Japan.
Advances in chronic thromboembolic pulmonary hypertension (CTEPH) treatment have improved prognosis, shifting focus towards symptom management. This study aimed to identify factors influencing the World Health Organization functional class (WHO-FC) in CTEPH patients. The CTEPH AC registry is a prospective, multicenter database from 35 Japanese institutions, analyzing data from August 2018 to July 2023.
View Article and Find Full Text PDFEfficacy of a novel interstitial lung disease monitoring program in breast cancer patients undergoing treatment with trastuzumab-deruxtecan.
Breast Cancer Res Treat
January 2025
Huntsman Cancer Institute at the University of Utah, Salt Lake City, UT, USA.
Purpose: Interstitial lung disease (ILD) is a well described and potentially fatal complication of trastuzumab-deruxtecan (T-DXd). It is currently unknown if specific monitoring is beneficial in the early detection of ILD in these patients. We describe the efficacy and feasibility of a novel ILD monitoring protocol in breast cancer patients treated with T-DXd at our institution.
View Article and Find Full Text PDFCombination of Biological Aging and Genetic Susceptibility Helps Identifying At-Risk Population of Venous Thromboembolism: A Prospective Cohort Study of 394 041 Participants.
Am J Hematol
January 2025
Zhongshan School of Medicine, Sun Yat-Sen University, Guangzhou, China.
Phenotypic age acceleration (PhenoAgeAccel) is a novel clinical aging indicator. This study was carried out to investigate the relationship between PhenoAgeAccel and the incidence of VTE, as well as to integrate PhenoAgeAccel with genetic susceptibility to improve risk stratification of VTE. The study included 394 041 individuals from the UK Biobank.
View Article and Find Full Text PDFMortality in Autoimmune Liver Disease in Sweden: A Population-Based Cohort Study of 9,654 Patients.
Liver Int
February 2025
Department of Medicine, Huddinge, Karolinska Institute, Stockholm, Sweden.
Background/aims: Epidemiological data on mortality in autoimmune liver diseases (AILDs) are scarce. We examined all-cause and cancer-related mortality in individuals with AILD from Sweden.
Methods: We identified 9654 individuals with AILD (3342 with autoimmune hepatitis (AIH), 3751 with primary biliary cholangitis (PBC), and 2561 with primary sclerosing cholangitis (PSC)) using national Swedish registries between 2001 and 2020.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!